loading...| Preferred Name | tofacitinib | |
| Synonyms |
CP-690550 CP-690,550 free base 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo(2,3-D)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile tasocitinib |
|
| Definitions |
An orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C95800" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95800" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000759505 |
|
| altLabel |
CP-690550 CP-690,550 free base 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo(2,3-D)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile tasocitinib |
|
| CAS Registry |
477600-75-2 |
|
| cui |
C3179368 C2930696 |
|
| DATE FIRST PUBLISHED |
2014-03-26 |
|
| Date last modified |
2014-05-30 |
|
| definition |
An orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C95800" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95800" NCI Thesaurus) |
|
| NCI ID |
C95800 |
|
| notation |
CDR0000759505 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
tofacitinib |
|
| tui |
T109 T121 |